A Rollover Protocol For Patients Who Received CP-675,206 In Other Protocols

Trial Profile

A Rollover Protocol For Patients Who Received CP-675,206 In Other Protocols

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 09 Mar 2017

At a glance

  • Drugs Tremelimumab (Primary)
  • Indications Colorectal cancer; Malignant melanoma; Prostate cancer; Renal cell carcinoma
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors AstraZeneca; MedImmune; Pfizer
  • Most Recent Events

    • 15 Nov 2016 Planned End Date changed from 1 Dec 2016 to 1 Dec 2017.
    • 15 Nov 2016 Planned primary completion date changed from 1 Dec 2016 to 1 Dec 2017.
    • 01 May 2016 This study is discontinued in Italy as per European Clinical Trials Database record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top